



European Monitoring Centre  
for Drugs and Drug Addiction

## **Pilot Exercise and template**

TDI Expert Meeting  
Lisbon 20th September 2012  
André Noor

# Pilot data providers

- Template pre May 2012
  - Czech Republic
  - Netherlands
  - England (EN)
- Template post May 2012
  - Poland (a subset of approx 5% of outpatient and 11% of inpatient units)
  - Estonia
  - Spain
- Attempt to obtain primary + 2 secondary drugs abandoned.
- Treatment centre list shortened



# Outline

- Scale
- New Categories
- Break variables
- Problem questions
- Health consequences questions
- Definitions



## Scale: Never Previously treated totals.

	2006	2007	2008	2009	2010	2011
Czech Republic	4119	4346	3981	4317	4362	4512
Estonia	:	:	176	157	176	151
Spain	22333	23034	22944	24605	26805	
Netherlands	5226	6078	6547	6196	6938	6854
Poland	6480	5690	6362	6252	379	
England PR 3					36703	
England PR 2					35256	



## Scale All treatments totals

<b>Country</b>	<b>2006</b>	<b>2007</b>	<b>2008</b>	<b>2009</b>	<b>2010</b>	<b>2011</b>
<b>Czech Republic</b>	<b>8164</b>	<b>8121</b>	<b>7934</b>	<b>8207</b>	<b>8484</b>	<b>8448</b>
<b>Estonia</b>	<b>:</b>	<b>:</b>	<b>625</b>	<b>687</b>	<b>665</b>	<b>436</b>
<b>Spain</b>	<b>49283</b>	<b>50555</b>	<b>53155</b>	<b>52549</b>	<b>53508</b>	
<b>Netherlands</b>	<b>9623</b>	<b>8718</b>	<b>10132</b>	<b>11650</b>	<b>12919</b>	<b>10817</b>
<b>Poland</b>	<b>13198</b>	<b>12582</b>	<b>14709</b>	<b>14408</b>	<b>1343</b>	
<b>England PR 3</b>					<b>94672</b>	
<b>England PR 2</b>					<b>94484</b>	



## New categories: Opioids

Drug	Country						Total
	CZ	EE	ES	NL	PL	EN	
Heroin	990	46	17,325	838	549	50,211	69,959
Methadone	29	8	645	185	8	3,688	4,563
Buprenorphine	437	0	3	0	0	1,037	1,477
Fentanyl	0	331	6	0	0	12	349
Opioids Other	155	12	395	115	89	1,950	2,716
<b>Total</b>	<b>1,611</b>	<b>397</b>	<b>18,374</b>	<b>1,138</b>	<b>646</b>	<b>56,898</b>	<b>79,064</b>



## New categories: Stimulants other than cocaine.

Drug	CZ	EE	ES	NL	PL	EN	Total
Amphetamines	8	11	500	695	283	2,463	3,960
Methamphetamines	5,476	0	17	0	3	34	5,530
MDMA+ derivatives	5	0	98	63	1	144	311
Synthetic cathinones	1	0	0	0	0	0	1
Stimulants other	10	0	39	29	8	283	369
<b>Total</b>	<b>5,500</b>	<b>11</b>	<b>654</b>	<b>787</b>	<b>295</b>	<b>2,924</b>	<b>10,171</b>



## New categories: Hypnotics and sedatives

Drug	Country					Total
	CZ	ES	NL	PL	EN	
Barbiturates	4	8	8	2	6	28
Benzodiazepines	27	875	265	19	926	2,112
GHB/GBL	0	4	382	0	93	479
Hypnotics/sedatives Other	32	57	0	13	0	102
<b>Total</b>	<b>63</b>	<b>944</b>	<b>655</b>	<b>34</b>	<b>1,025</b>	<b>2,721</b>





# New categories: Hallucinogens

Drug	Country					Total
	CZ	ES	NL	PL	EN	
LSD	2	2	1	0	9	14
Ketamine	0	46	12	0	463	521
Hallucinogens other	1	21	1	2	16	41
<b>Total</b>	<b>3</b>	<b>69</b>	<b>14</b>	<b>2</b>	<b>488</b>	<b>576</b>



## Other substances not specified

<b>Drug</b>	<b>CZ</b>	<b>ES</b>	<b>NL</b>	<b>PL</b>	<b>EN</b>	<b>Total</b>
<b>Other substances total</b>	<b>27</b>	<b>54</b>	<b>133</b>	<b>25</b>	<b>199</b>	<b>438</b>
<b>Total</b>	<b>27</b>	<b>54</b>	<b>133</b>	<b>25</b>	<b>199</b>	<b>438</b>



## New categorisations.

- Categorisations were changed to match international standards.
- Countries are now fitting existing categorisations to new categories where possible.



## New Categories: Minor problems

- Source of referral
- Living status with whom
- Living status with children
- Labour status
- Injecting frequency
- Frequency of use.
  - 2 - 6 days per week



# Break variables

- All/Never previously treated/Previously treated  
Missing to be calculated
- Never previously treated + Previously treated  $\leq$  All
- Primary drug by treatment centre
  - 4 out of 6 <
  - 1 =
  - 1 an error in the all table when compared to other tables.
- Treatment centre types
- Sex



# Problem questions.

- Lag to treatment
  - Half of the countries faced problems
  - Needs clearer explanation
- Polydrug use question
  - In the protocol the definition is demanding
  - The numbers don't match this
  - Difficult to interpret
- Primary drug by living status with children



# Health consequences questions

		CZ	NL	UK	EE	ES	PL
21.1	HIV testing by injecting behaviour	1	0	0	0	0	1
22.1	HCV testing by injecting behaviour	1	0	0	0	0	1
23.1	Needles syringe sharing	1	0	0	1	0	1
24.1	Primary drug by years since first injection	1	0	0	1	0	1
25.1	OST status	0	1	0	0	0	1
26.1	Primary drug by years since first OST	0	1	0	0	0	0



## Suggestion: Definitions

- 19 definitional questions
- Is it necessary to collect these annually?
- Could these be collected periodically?





## Next steps

- Further analysis of the pilot data
- Correction of the template
- Final version distributed





European Monitoring Centre  
for Drugs and Drug Addiction

**TDI Revision :**

**Data Pilot**

28th May 2012 – Lisbon

# Principles

- Improve the possibility of analysis
  - Methodology
  - Move from gender to drugs
  - Time variables
- Correct anomalies
  - Treatment status
  - Categories
- Minimise the burden
  - Reduce the number of reports submitted



## Methodology questions (3.\*)

- Emphasis on improving our understanding of the TDI collection within the country.
- Areas
  - Coverage (3.1.\*).
  - Double counting controls (3.2.\*).
  - Definitions (case, episode, treatment centre type)(3.3.\*)
  - Source (3.4.\*)
  - Remarks (3.5)
- During submission, these can be copied from the previous year if no changes



# Treatment status:

- **Currently:**
  - All treatments.
  - First treatments.
- **Pilot:**
  - All treatment entrants
  - Never previously treated
  - Previously treated
- **Missing values calculated by subtraction**



# Treatment centre type

- **Currently:**
  - Reports were submitted by treatment centre type.
  - Most countries submitted at least 2 reports.
  - Possible submission of 5 reports.
- **Pilot:**
  - Each country submits one report.
  - Treatment centre type is a variable.  
Type of treatment centre by:
    - Coverage (3.1.1).
    - Double counting control (3.2.1 ).
    - Treatment status (reference table for grand totals 4.1.1).
    - Primary drug (5.1.1).



	country	collyear	datayear	treatevent	drug	data1	data2	data3	data4	data5	data6	data7	data8
1.	CZ	2012	2011	All Opioids Total	1193	421	0	0	693	0	0	1611	
2.	EE	2011	2011	All Opioids Total	302	3	26	0	0	66	0	397	
3.	ES	2012	2010	All Opioids Total	18374	0	0	0	0	0	0	0	
4.	NL	2012	2010	All Opioids Total	972	166	0	0	0	0	0	1138	
5.	PL	2012	2010	All Opioids Total	109	537	.	.	.	.	.	646	
6.	UK	2012	2010	All Opioids Total	50850	2851	0	3197	0	0	0	56898	
7.	CZ	2012	2011	Never previously	Opioids Total	131	110	0	0	202	0	0	443
8.	EE	2011	2011	Never previously	Opioids Total	94	3	0	0	0	23	0	120
9.	ES	2012	2010	Never previously	Opioids Total	4881	0	0	0	0	0	0	0
10.	NL	2012	2010	Never previously	Opioids Total	322	44	0	0	0	0	0	366



# Treatment Centre Types

- Outpatient
  - Specialised treatment
  - General practitioners
  - Low threshold agencies
  - Other
- Inpatient
- Prison
- Other (please specify)
- Not Known





# Drugs: Primary categories have not changed

- Opioids
- Cocaine
- Stimulants other than cocaine
- Hypnotics and sedatives
- Hallucinogens
- Volatile inhalants
- Cannabis
- Other substance (please specify)
- Not known/missing



# Drugs: Secondary categories Opioids

- Emphasis has been placed on
  - Reporting the misuse of drugs used in the treatment of opioid addiction
  - Allowing countries with specific drug use patterns to report more accurately
- Methadone misused
- Buprenorphine misused
- Fentanyl illicit/misused



# Drugs: Secondary categories Other changes

- Stimulants other than cocaine
  - Methamphetamines
  - Synthetic cathinones
- Hypnotics and sedatives
  - GHB/GBL
- Hallucinogens
  - Ketamine
- Other substances (please specify)



## Drug breakdown replaces Sex breakdown

- Primary drug by source of referral (8.1.\*).
- Primary drug by living status (where) (10.1.\*).
- Primary drug by educational level (11.1.\*).
- Primary drug by labour status (12.1.\*).



## Drug breakdown replaces Treatment status breakdown

- For the following two socio-demographic variables, a sex breakdown was considered more important than a breakdown by “never previously treated” and previously treated”
- Primary drug by living status (with whom) and Sex (9.1.\*)
- Primary drug by living status (with children) and Sex (10.1.\*)



## Sex: Totals retained but sex breakdown lost.

- Treatment status
  - (current 4.1 ; pilot 4.1.1).
- Primary drug by Age (grouped).
  - (current 12.1.\*, 13.1.\*, 14.1.\* ; pilot 7.1.\*).
- Primary drug by Age at first use (grouped).
  - (current 21.1.\*, 22.1.\*, 23.1.\* ; pilot 16.1.\*).
- Primary drug by Route of administration.
  - (current 15.1.\*, 16.1.\* , 17.1.\* ; pilot 14.1.\*).
- Primary drug by Frequency of use.
  - (current 18.1.\*, 19.1.\* , 20.1.\* ; pilot 15.1.\*).
- Injecting behaviour.
  - (current 25.1.\* ; pilot 23.1.\*).



## Sex: Retained.

- Primary drug by Sex (6.1.1 to 6.1.3)
- Mean ages (6.1.4 to 6.1.9)
- Socio-demographic
  - Primary drug by living status (with whom) and Sex (9.1.\*)
  - Primary drug by living status (with children) and Sex (10.1.\*)



## Time: Mean ages by Primary drug, Sex and Treatment status (6.1.4 to 6.1.9).

- Age at entering treatment
- Age at first use
- Lag to treatment
  - Age at entering treatment – age at first use.





## Time: Age distributions (7.1.\*, 16.1.\*)

- Primary drug by age (grouped) and treatment status (7.1.\*).
- Primary drug by age at first use (grouped) and treatment status (16.1.\*)
- Loss: Breakdown by Males and Females.



## Time: Duration/Time since (17.1.\*, 24.1.\*) New questions and new format

- Primary drug by Years since first use and Treatment status (17.1.\*)
  - Current treatment entry date – first use date
- Primary drug by Years since first drug injection and Treatment status (24.1.\*)
  - Current treatment entry date – first year of injection
- Primary drug by Years since first OST (25.1.2)
  - Current treatment entry date – first year of OST



# Drug use patterns

- The primary drug categorisation remains central to the data collection.
  - The drug causing the most serious problem and the main reason the client has entered treatment. (see Protocol 2.1.7)
- Emphasis on:
  - a limited definition of polydrug use
  - capturing drug use combinations (20.1.\*)
- New
  - 19 Polydrug use by treatment status.
- Changed format
  - 20 Primary drug by secondary drug.



# Drug use patterns: Polydrug use (19.1)

- Limited definition:
  - “when two or more psychoactive substances are known to be involved, but it is impossible to assess which substance is contributing most to the disorder”
- To be used when it is not possible to assign a primary drug.



# Drug use patterns: primary and secondary drugs (20.1.\*)

- New structure:
  - Tables by primary drug group.
  - Allows up to two secondary drugs to be entered.
  - Totals should match drug group totals.
- Sex has been dropped.



## Health consequences:

- 21 HIV testing by injecting behaviour
  - 22 HCV testing by injecting behaviour
  - 23 Needle sharing by injecting behaviour.
  - 24 Primary drug by years since first injection.
  - 25 Clients receiving OST.
- 
- 18 Drug (any) by injecting behaviour



# Request

- Submit pilot data.
- Inform of feasibility.
- Inform of improvements/suspected errors in wording or format



# Timeline

- 15th March Draft template distributed
- 28th May review meeting
  - Feedback from UK
  - Small corrections
  - Construct Fonte template
- 29th June receive pilot data?
  - Fonte/Excel submit to AN.
- 19th September TDI Expert Meeting
  - Feedback preliminary results





Thank you.

